2022-502137-26-00招募中1 期
A Trial to Study if REGN5837 in Combination with Odronextamab is Safe for Adult Participants with Aggressive B-cell Non-Hodgkin Lymphomas
Regeneron Pharmaceuticals Inc.7 个研究点 分布在 3 个国家目标入组 42 人开始时间: 2023年8月23日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 42
- 试验地点
- 7
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Medical Affairs
Scientific
Regeneron Pharmaceuticals Inc.
研究点 (7)
Loading locations...
相似试验
已完成
1 期
A trial to learn if different doses of REGN17092 are safe in healthy adults2023-505041-52-00Regeneron Pharmaceuticals Inc.128
已完成
1 期
A trial to learn if REGN7999 is safe and well tolerated, and how it works in the body of healthy participants.2022-500398-15-00Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc.64
招募中
1 期
A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control2024-519277-18-00F. Hoffmann-La Roche AG40
招募中
1 期
A Phase I Study of RO7589831 Alone and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors2023-503170-20-01F. Hoffmann-La Roche AG46
招募中
1 期
A study investigating the safety of RO7795074, a new compound that may potentially be used in the treatment of type 1 diabetes, and the effect of RO7795074 on how the body processes pitavastatin2025-521921-34-00Genentech Inc.32